Subject: Re: China MedConnect follow up
From: "Eric Schwerin" <[email-masked]>
To: "Hunter Biden" <[email-masked]>
Date: Mon, 22 Sep 2014 13:28:31 -0400

On the RSPI side this seems that if they are legit this could be right up CITIC’s alley.  They have a big medical device/healthcare practice with relationships with hospitals as well.  They’d be willing to make an investment and manufacture over there.   Unless that would be in conflict with BHR or any other potential Chinese partner that would be the main way I’d see going on the capital raising side.  

Eric D. Schwerin
Rosemont Seneca Partners, LLC
1010 Wisconsin Ave., NW
Suite 705
Washington, DC 20007
(202) 333-1880
[email-masked]
P Consider the environment before printing this email.

On Sep 22, 2014, at 12:51 PM, Hunter Biden <[email-masked]> wrote:

> Take a look below. I'd like to provide Clean Fuze (thru Paul Rowan) with two memos. 1- from RS Advisors re mkt entry into China- our opinion on China Med Connect (are they legit etc...), and how we could help on the ground and 2- a memo from RSPI on our capacity to raise capital and/ or take on the role of consummating a deal w/ Chinese partner.
> 
> RHB
> 202.333.1880
> 
> Begin forwarded message:
> 
>> From: Paul <[email-masked]>
>> Date: September 18, 2014 at 3:28:27 PM EDT
>> To: Hunter <[email-masked]>
>> Subject: Fwd: China MedConnect follow up
>> 
>> FYI
>> 
>> Sent from my iPhone
>> 
>> Begin forwarded message:
>> 
>>> From: Derrick Johns <[email-masked]>
>>> Date: September 18, 2014 at 11:25:34 AM EDT
>>> To: Ellen Zehna <[email-masked]>
>>> Subject: Re: China MedConnect follow up
>>> 
>>> Hi Ellen,
>>> 
>>> My co-founder and I were just discussing China last week as we have significant IP which has issued and is about to issue.   We also have a manufacturing process patent which is about to issue in China and has issued in Hong Kong.
>>> 
>>> Our antimicrobial polymer CleanFuze has been CE Marked and we have a high interest in the following courses within China;
>>> 
>>> 	- Manufacturing in China: extrusion of PEEK and CNC machining as a cost reduction measure
>>> 	- Selling to Chinese Hospitals: surgical infection is the 4th largest cause of death in the US – I suspect the %’s are equally concerning in China.
>>> 	- Potential Growth Capital Investment from Chinese Sources
>>> 	- Chinese Subsidiary of Difusion on mainland China
>>> 	- Future acquisition by Chinese Company
>>> 
>>> We are an ISO 13845 entity and have a large R&D pipeline for orthopedic and dental applications.  I have attached our introductory stack for your review.   We are happy to do a call next week any time but the 23rd.
>>> 
>>> Derrick W. Johns
>>> CEO and Founder
> <1D44E4A7-AEC9-4D1E-A8ED-AAE1A3C8FDAD[25].png>
>>> www.difusiontech.com
>>> 
>>> “Idleness is sweet,
>>>        Its consequences are cruel”
>>>   
>>> (512) 863-7777 o
>>> (512) 284-3338 c
>>> 
>>> 
>>> 
>>> From: Ellen Zehna <[email-masked]>
>>> Date: Thursday, September 18, 2014 at 10:11 AM
>>> To: Derrick Johns <[email-masked]>
>>> Subject: China MedConnect follow up
>>> 
>>> Hello Derrick,
>>> 
>>> As a follow-up to my phone call, I wanted to send this brief introduction and also see if we can schedule a conversation to determine whether or not we might be of service to your company.
>>> 
>>> China MedConnect is an advisory and operations company incorporated in the U.S. with primary business operations in Beijing, China.  We are a member of the US Commercial Services solution provider program for China and are a recognized China medical device expert.  We are focused exclusively on supporting small to medium-sized Western medical device companies with their operations and interests in mainland China.
>>> 
>>> We are established as a US company with a China based subsidiary so that we engage in legal agreements US-to-US rather than China-to-US. Although our reputation is our business and we like to think of ourselves as having high integrity, we do this as a risk mitigation for VC backed companies and others who may have concerns about doing business in China.
>>> 
>>> We offer a comprehensive set of services designed to assist companies at all stages of growth in China to accelerate time to market and enable best practices at a lower cost and risk than doing so independently.  We can perform deep market analysis, competitive and opportunity assessments, market entry planning and execution, expansion and investment partnering strategies, as well as connectivity to our trusted network of high quality Tier 1 distributors in order to increase market penetration. 
>>> 
>>> Through our wholly-owned PRC subsidiary (Beijing Jinshida), we are licensed to perform as CFDA Registration Agent, Legal Agent, and After Sales Service Agent for western medical device companies.  We preserve options to change direction and strategy in a rapidly changing and dynamic market.
>>>  
>>> We can help with sourcing.  We can also fund market entry on product lines that have a distinct and compelling value proposition for the China market.
>>> 
>>> Our clients are a mix of those already in China and those interested in entering the market. Generally, we find they are frustrated by the lack of transparency, a low level of trust in their relationships and communications, and a very complex and rapidly changing environment.
>>>     
>>> Please let me know if this is of interest and if we can schedule a quick call to explore whether or not we can help with any of your needs or interests regarding China.
>>>  
>>> Alternatively, I can send you additional information or you can learn more about us at www.chinamedconnect.com
>>>     
>>> Best regards,
>>> 
>>> Ellen Zehna
>>> Business Development Manager
>>> U.S. -- California Office
>>> 408-310-7437
>>> www.chinamedconnect.com
> <Chinese Bone Growth Patent (2).pdf>
> <DiFusion Corp  Intro.pptx>
> <Us Manufacturing Patent Difusiion.pdf>
> <1D44E4A7-AEC9-4D1E-A8ED-AAE1A3C8FDAD[25].png>